



March 01, 2018

To  
**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051,  
Maharashtra, India

To  
**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001,  
Maharashtra, India

Dear Sir/Madam,

**Sub :** **Intimation regarding execution of Business Transfer Agreement (“BTA”) by HealthCare Global Enterprises Limited (“the Company”),**

**Ref :** **Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Scrip Code :** **NSE Scrip Code: HCG; BSE Scrip Code: 539787**

In continuation of the intimation made to the stock exchanges by the Company on February 8, 2018, the Company is hereby informing you that, the Company has entered into a BTA with one of the Company’s promoters, Dr. M. Gopichand (“Seller”) on February 28, 2018, for the purchase of business of City Cancer Centre, a cancer care hospital, located at CH Venkata Krishnayya Street, Vijayawada 520 002, Andhra Pradesh, owned by the Seller (“Business Undertaking” or “the Target Entity”).

The Company presently operates one cancer care centre each in Vijayawada and Ongole and a PET CT centre in Vijayawada (“collectively referred to as HCG Vijayawada”). The purchase of the Business Undertaking by the Company provides an opportunity to consolidate the business of HCG Vijayawada and the Business Undertaking under the Company. Dr. M. Gopichand, a renowned Surgical Oncologist in Vijayawada, has also entered into a consultancy agreement with the Company to provide medical consultancy services on an exclusive basis.

**Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015:**

*(a) Name of the target entity, details in brief such as size, turnover, etc.;*

The Target Entity is, a well renowned cancer care hospital, having 64 operational beds, owned by the Seller, operating under the name City Cancer Centre, located at CH Venkata Krishnayya Street, Vijayawada 520002, Andhra Pradesh. The turnover of the Target Entity in FY 2017 was INR 165.5 Million.

**HealthCare Global Enterprises Limited**

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



*(b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;*

The acquisition would not fall within the meaning of ‘related party transaction’. While, Dr M. Gopichand is one of the Promoters of the Company, he is not a ‘related party’. The transaction under the BTA is at arm’s length.

*(c) Industry to which the entity being acquired belongs;*

The Target Entity is a provider of healthcare services, focusing on cancer care.

*(d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);*

The purchase of the Business Undertaking by the Company provides an opportunity to consolidate the business of HCG Vijayawada and the Business Undertaking under the Company thereby improving performance, efficiency and brand visibility.

The business of the Target Entity is in the same line as that of the Company.

*(e) Brief details of any governmental or regulatory approvals required for the acquisition;*

Not Applicable.

*(f) Indicative time period for completion of the acquisition;*

The consummation of transaction under the BTA is effective from January 01, 2018, and is expected to be completed by or before May 30, 2018.

*(g) Nature of consideration - whether cash consideration or share swap and details of the same;*

The consideration payable to the Seller for the acquisition of the Target Entity would be in the form of cash and issuance of shares of the Company. The issuance of shares to the Seller will be made on a preferential issue basis, and is subject to the approval of the shareholders, for which a shareholders’ meeting is being called.

*(h) cost of acquisition or the price at which the shares are acquired;*

The consideration for the purchase of the business of the Target Entity is INR 52,00,00,000 (Indian Rupees Fifty-Two Crores Only) payable partly by way of cash and by way of issuance of shares of the Company to the Seller, in tranches, which is as under:



- (a) INR 15,00,25,500 (Rupees Fifteen Crores Twenty-Five Thousand Five Hundred Only) in cash, payable by March 15, 2018.
- (b) Issuance of 9,34,500 equity shares of the Company at Rs. 321, (Indian Rupees Three Hundred and Twenty-One Only) per equity share, aggregating to Rs. 29,99,74,500 (Indian Rupees Twenty-Nine Crores Ninety-Nine Lakhs Seventy-Four Thousand Five Hundred only) subject to obtaining the approval of the shareholders of the Company.
- (c) INR 7,00,00,000 (Indian Rupees Seven Crores only), if the combined business achieves certain performance criteria as agreed upon by the Company and the Seller, for the next financial year ending March 31, 2019.

*(i) percentage of shareholding / control acquired and / or number of shares acquired;*

The Target Entity is a sole proprietary concern and hence not applicable.

*(j) brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief);*

The Target Entity was established in 1999 by the Seller in Vijayawada, Andhra Pradesh, for providing cancer care services. The acquisition of the Business Undertaking would augment the clinical team of HCG Vijayawada, and Dr. Gopichand would have an exclusive arrangement to work with HCG Vijayawada, hereon.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

**For HealthCare Global Enterprises Limited**

**SUNU MANUEL** Digitally signed by SUNU MANUEL  
Date: 2018.03.01 21:49:10 +05'30'

**Sunu Manuel**  
**Company Secretary & Compliance Officer**



The Specialist  
in Cancer Care

adding life to years

March 01, 2018

To  
National Stock Exchange of India Limited,  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051,  
Maharashtra, India

To  
BSE Limited,  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001,  
Maharashtra, India

Dear Sir/Madam,

**Sub :** Intimation regarding execution of Business Transfer Agreement (“BTA”) by HealthCare Global Enterprises Limited (“the Company”),

**Ref :** Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Scrip Code :** NSE Scrip Code: HCG; BSE Scrip Code: 539787

In continuation of the intimation made to the stock exchanges by the Company on February 8, 2018, the Company is hereby informing you that, the Company has entered into a BTA with one of the Company’s promoters, Dr. M. Gopichand (“Seller”) on February 28, 2018, for the purchase of business of City Cancer Centre, a cancer care hospital, located at CH Venkata Krishnayya Street, Vijayawada 520 002, Andhra Pradesh, owned by the Seller (“Business Undertaking” or “the Target Entity”).

The Company presently operates one cancer care centre each in Vijayawada and Ongole and a PET CT centre in Vijayawada (“collectively referred to as HCG Vijayawada”). The purchase of the Business Undertaking by the Company provides an opportunity to consolidate the business of HCG Vijayawada and the Business Undertaking under the Company. Dr. M. Gopichand, a renowned Surgical Oncologist in Vijayawada, has also entered into a consultancy agreement with the Company to provide medical consultancy services on an exclusive basis.

**Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015:**

(a) *Name of the target entity, details in brief such as size, turnover, etc.;*

The Target Entity is, a well renowned cancer care hospital, having 64 operational beds, owned by the Seller, operating under the name City Cancer Centre, located at CH Venkata Krishnayya Street, Vijayawada 520002, Andhra Pradesh. The turnover of the Target Entity in FY 2017 was INR 165.5 Million.

(b) *Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”*

**HealthCare Global Enterprises Ltd.**

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489







The acquisition would not fall within the meaning of 'related party transaction'. While, Dr M. Gopichand is one of the Promoters of the Company, he is not a 'related party'. The transaction under the BTA is at arm's length.

*(c) Industry to which the entity being acquired belongs:*

The Target Entity is a provider of healthcare services, focusing on cancer care.

*(d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):*

The purchase of the Business Undertaking by the Company provides an opportunity to consolidate the business of HCG Vijayawada and the Business Undertaking under the Company thereby improving performance, efficiency and brand visibility.

The business of the Target Entity is in the same line as that of the Company.

*(e) Brief details of any governmental or regulatory approvals required for the acquisition:*

Not Applicable.

*(f) Indicative time period for completion of the acquisition:*

The consummation of transaction under the BTA is effective from January 01, 2018, and is expected to be completed by or before May 30, 2018.

*(g) Nature of consideration - whether cash consideration or share swap and details of the same:*

The consideration payable to the Seller for the acquisition of the Target Entity would be in the form of cash and issuance of shares of the Company. The issuance of shares to the Seller will be made on a preferential issue basis, and is subject to the approval of the shareholders, for which a shareholders' meeting is being called.

*(h) cost of acquisition or the price at which the shares are acquired:*

The consideration for the purchase of the business of the Target Entity is INR 52,00,00,000 (Indian Rupees Fifty-Two Crores Only) payable partly by way of cash and by way of issuance of shares of the Company to the Seller, in tranches, which is as under:


- a) INR 15,00,25,500 (Rupees Fifteen Crores Twenty-Five Thousand Five Hundred Only) in cash, payable by March 15, 2018.
- b) Issuance of 9,34,500 equity shares of the Company at Rs. 321, (Indian Rupees Three Hundred and Twenty-One Only) per equity share, aggregating to Rs. 29,99,74,500 (Indian Rupees Twenty-Nine Crores Ninety-Nine Lakhs Seventy-Four Thousand Five Hundred only) subject to obtaining the approval of the shareholders of the Company.
- c) INR 7,00,00,000 (Indian Rupees Seven Crores only), if the combined business achieves certain performance criteria as agreed upon by the Company and the Seller, for the next financial year ending March 31, 2019.

*(i) percentage of shareholding / control acquired and / or number of shares acquired:*

**HealthCare Global Enterprises Ltd.**

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489





The Specialist  
in Cancer Care

adding life to years

The Target Entity is a sole proprietary concern and hence not applicable.

- (i) *brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief);*

The Target Entity was established in 1999 by the Seller in Vijayawada, Andhra Pradesh, for providing cancer care services. The acquisition of the Business Undertaking would augment the clinical team of HCG Vijayawada, and Dr. Gopichand would have an exclusive arrangement to work with HCG Vijayawada, hereon.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel  
Company Secretary & Compliance Officer



**HealthCare Global Enterprises Ltd.**

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | [info@hcgoncology.com](mailto:info@hcgoncology.com) | [www.hcgoncology.com](http://www.hcgoncology.com) | CIN : L15200KA1998PLC023489